前房内莫西沙星预防性用药降低眼内炎发生率:60万例手术分析
该回顾性临床登记研究分析了2014年1月至2016年5月印度10家Aravind眼科医院全部617453例白内障手术,比较前房内莫西沙星预防前后眼内炎发生率。总体眼内炎发生率从0.07%降至0.02%(P<0.001),超声乳化从0.07%降至0.01%,手法小切口白内障手术从0.07%降至0.02%,后囊膜破裂眼从0.48%降至0.21%(P=0.034)。结论认为常规前房内莫西沙星预防可降低眼内炎发生率,后囊膜破裂高危人群应强烈考虑前房内抗生素预防。
要点
- 总体眼内炎发生率从0.07%(214/302815)降至0.02%(64/314638)(P<0.001)。
- 超声乳化眼内炎发生率从0.07%(75/104894)降至0.01%(11/89358)(P<0.001)。
- 后囊膜破裂眼未用莫西沙星时眼内炎发生率为0.48%(20/4186),用药后降至0.21%(9/4293)(P=0.034)。
核心结论
- 常规前房内莫西沙星预防使总体眼内炎发生率降低约3.5倍(手法小切口白内障手术降低3倍,超声乳化降低近6倍)。
- 后囊膜破裂眼使用前房内莫西沙星也有统计学获益,作者认为该高危人群应强烈考虑前房内抗生素预防。
- 莫西沙星似乎是选择前房内抗生素预防的外科医生的有效选择。
研究设计与样本
- 回顾性临床登记研究,纳入2014年1月至2016年5月29个月期间印度10家Aravind眼科医院全部617453例白内障手术。
- 分析所有研究眼的电子健康记录数据,比较前房内莫西沙星使用前后眼内炎发生率,并分别分析超声乳化和手法小切口白内障手术及后囊膜破裂眼。
主要发现
- 总体302815眼未接受前房内莫西沙星,314638眼接受,眼内炎发生率从0.07%(214/302815)降至0.02%(64/314638)(P<0.001)。
- 超声乳化194252眼中,未预防组眼内炎发生率为0.07%(75/104894),预防组为0.01%(11/89358)(P<0.001)。
- 手法小切口白内障手术414657眼中,未预防组眼内炎发生率为0.07%(135/192149),预防组为0.02%(52/222508)(P<0.001)。
- 8479例后囊膜破裂眼中约半数接受前房内莫西沙星,未用药时后囊膜破裂使眼内炎发生率增加近7倍至0.48%(20/4186),用药后降至0.21%(9/4293)(P=0.034)。
- 无不良事件归因于前房内莫西沙星。
临床怎么用
- 作者认为,对于后囊膜破裂这一高危人群,应强烈考虑前房内抗生素预防。
- 作者认为,鉴于万古霉素与出血性闭塞性视网膜血管炎的关联以及前房内头孢呋辛在许多国家无商业供应,莫西沙星似乎是选择前房内抗生素预防的外科医生的有效选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the postoperative endophthalmitis rate before and after initiation of intracameral (IC) moxifloxacin prophylaxis for both phacoemulsification and sutureless, manual small-incision cataract surgery (M-SICS), as well as in patients with posterior capsular rupture (PCR). DESIGN: Retrospective, clinical registry. PARTICIPANTS: All cataract surgeries (617 453) performed during the 29-month period from January 2014 to May 2016 at the 10 regional Aravind eye hospitals were included. METHODS: The electronic health record data for all study eyes were analyzed. Endophthalmitis rates before and after moxifloxaxin were statistically compared for all eyes and separately for both phacoemulsification and M-SICS, and for the eyes complicated by PCR. MAIN OUTCOME MEASURES: The postoperative endophthalmitis rates before and after initiation of IC moxifloxacin prophylaxis. RESULTS: Overall, 302 815 eyes did not receive IC moxifloxacin and 314 638 eyes did, and there was a significant decline in the endophthalmitis rate, from 0.07% (214/302 815) to 0.02% (64/314 638) (P < 0.001), with moxifloxacin. For the 194 252 phacoemulsification eyes, the endophthalmitis rate was 0.07% (75/104 894) without IC moxifloxacin prophylaxis, compared with 0.01% (11/89 358) with moxifloxacin (P < 0.001). For the 414 657 M-SICS eyes, the endophthalmitis rate was 0.07% (135/192 149) without IC moxifloxacin prophylaxis, compared with 0.02% (52/222 508) with moxifloxacin (P < 0.001). Approximately half of the 8479 eyes that had PCR received IC moxifloxacin, and half did not. Without IC moxifloxacin, PCR increased the endophthalmitis rate nearly 7-fold to 0.48% (20/4186); IC moxifloxacin reduced the endophthalmitis rate with PCR to 0.21% (9/4293) (P = 0.034). No adverse events were due to IC moxifloxacin. CONCLUSIONS: Routine IC moxifloxacin prophylaxis reduced the overall endophthalmitis rate by 3.5-fold (3-fold for M-SICS and nearly 6-fold for phacoemulsification). There was also a statistical benefit for eyes complicated by PCR, and IC antibiotic prophylaxis should be strongly considered for this high-risk population. These conclusions are strengthened by the high volume of cases analyzed at a single hospital network over a comparatively short time frame. Considering the association of hemorrhagic occlusive retinal vasculitis with vancomycin and the commercial unavailability of IC cefuroxime in many countries, moxifloxacin appears to be an effective option for surgeons electing IC antibiotic prophylaxis.
引用
- Haripriya A, Chang DF, Ravindran RD, et al. Endophthalmitis Reduction with Intracameral Moxifloxacin Prophylaxis: Analysis of 600 000 Surgeries. Ophthalmology. 2017. PMID: 28214101. doi:10.1016/j.ophtha.2017.01.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。